Bio/Pharma Outsourcing Innovation February 2024 eBook
Read the article:
Read the eBook:
Feature|Articles|February 15, 2024
- Bio/Pharma Outsourcing Innovation, February 2024 eBook
- Volume 2024 eBook
- Issue 2
- Pages: 26-30
Ensuring Quality in Contracted Support
Author(s)Iain McGhee
This article looks at the relationship between a CDMO quality organization and the client.
Advertisement
Working with a contract development and manufacturing organization (CDMO) is a great way for smaller or diversified biotech companies, and even Big Pharma, to expand operations or modalities to reach the patients more efficiently. Outsourcing process development and manufacturing requires a lesser upfront investment with faster timelines while allowing teams at advanced therapy developers to focus on innovation. However, this relationship can deeply impact the quality and efficacy of a product. This article explores the balancing act of ensuring regulatory compliance via internal procedures at a CDMO and what to consider when starting
this relationship.
About the author
Iain McGhee is vice president of Quality at Ascend.
Article details
Pharmaceutical Technology: Bio/Pharma Outsourcing Innovation eBook
February 2024
Issue 2
Pages: 26-30
Citation
When referring to this article, please cite it as McGhee, I. Ensuring Quality in Contracted Support. Pharmaceutical Technology, Bio/Pharma Outsourcing Innovation eBook. February 2024.
Read this
Articles in this issue
over 2 years ago
Pharmaceutical Outsourcing Present and Futureover 2 years ago
Managing the Complexity of Modern Sterile Product Developmentsover 2 years ago
Navigating the Preclinical CRO Outsourcing Processover 2 years ago
A Closer Look at Affinity Ligandsover 2 years ago
How to Evaluate a CDMO’s Commitment to QualityAdvertisement
Related to this article
Jane Zhang of ETCH Sourcing explains why geopolitics, transparency, and partnership now weigh as heavily as cost and quality when companies choose suppliers, in this episode of Ask the Expert, moderated by Susan J. Schniepp of Nelson Labs.
FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.
Manish Baviskar, Hubot CDMO, explains which AI skills validation engineers need first and why AI model updates must go through GMP change control.
Aleksandra Zuraw, senior veterinary pathologist at Charles River, discusses how chain of custody, good laboratory practice, quality control, and validation are applied to digital pathology data used in drug development.
FDA draft guidance on individualized genome editing lets BLAs add patient-specific variants without new trials, shifting evidence to CMC assay data.
Vibha Jawa, PhD, chief scientific officer at EpiVax, explains why the need for animal studies varies by modality and what it takes for organ-on-chip and other human-relevant models to replace these studies in IND-enabling toxicology work.
Sanjay Konagurthu, PhD, senior director of Science and Innovation at Thermo Fisher Scientific, explains what teams need to do to ensure the usefulness of AI and what strides have been made with AI in regulatory submissions.
This week on PharmTech.com, experts discussed E&L suitability standards, rare disease treatment development, sourcing ingredient suppliers, the use of AI in quality control, and more.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
From URS to Acceptance Evidence: Defining and Testing Interfaces in Pen Injector Assembly
2
AAPS PharmSci 360 2026: IND-Enabling Studies vs Animal Data
3
PharmTech Weekly Roundup—October 23, 2026: CMC Considerations, Rare Disease Development, Standards Harmonization
4
Formulation Risk Needs One Accountable Owner: AAPS PharmSci 360 2026
5